California official throws wrench in planned CVS-Aetna merger

The planned merger of CVS Health and Aetna hit a snag this week after California Insurance Commissioner Dave Jones urged the U.S. Department of Justice (DOJ) to block the $69 billion deal.

The news comes as investor Carl Icahn stated he would vote against the $54 billion purchase of Express Scripts Holdings by Cigna Corporation, The Wall Street Journal reported. The letter to DOJ is the first significant roadblock in CVS’s attempt to acquire Aetna. Last month, antitrust enforcers appeared less likely to move to block the deal, according to Bloomberg.

Jones took issue with the loss of Aetna as a competitor in the pharmacy benefit manager (PBM) market, announcing his findings and recommendations based on an in-depth review and analysis of the testimony, studies and written comments of a public hearing with expert testimony on the merger.

"A merger of this size and type, according to experts on health insurer and healthcare mergers, will likely lead to increased prices and decreased quality,” Jones said in a statement. “Further, partial divestiture or other remedies traditionally used by the Department of Justice will not adequately protect consumers or address the adverse consequences of a merger of CVS and Aetna. Traditional methods to avoid market concentration will not address potential impacts on service quality, the power to charge excessive rates, or the creation of barriers to block a potential market participant with the resources to enter into new markets.”

New entrants into the PBM space will also not be able to compete, he concluded. He requested that DOJ sue to block the transaction.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.